Jean-Jacques Kiladjian

38PUBLICATIONS
171CO-AUTHORS
Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markersHaematological tumoursPsycholinguistics (incl. speech production and comprehension)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Apr 17, 2026
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing.

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

|Mar 04, 2026
Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.

Alessandro M Vannucchi, Jay L Patel, Jean-Jacques Kiladjian

|Nov 17, 2025
Response to the commentary by Xu et al. on the PV-AIM study.

Florian H Heidel, Martin Griesshammer, Jean-Jacques Kiladjian

|Jun 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patients.

Olivier Mansier, Eric Lippert, Lina Benajiba

Pageof 7

Frequent Collaborators

10 joint publications

Bruno Cassinat

8 joint publications

John Mascarenhas

8 joint publications

Alessandro Vannucchi

7 joint publications

Srdan Verstovsek